



STUDY PROTOCOL

REVISED Neonatal iron distribution and infection susceptibility in full term, preterm and low birthweight babies in urban Gambia: study protocol for an observational study. [version 2; peer review: 2 approved]

James H. Cross, Ousman Jarjou , Nuredin Ibrahim Mohammed , Andrew M. Prentice, Carla Cerami

MRC Unit The Gambia at the London School of Hygiene & Tropical Medicine, Fajara, The Gambia

v2 First published: 21 May 2019, 3:1469
<https://doi.org/10.12688/gatesopenres.12963.1>
 Latest published: 15 Oct 2019, 3:1469
<https://doi.org/10.12688/gatesopenres.12963.2>

Abstract

Background: Neonatal infection is the third largest cause of death in children under five worldwide. Nutritional immunity is the process by which the host innate immune system limits nutrient availability to invading organisms. Iron is an essential micronutrient for both microbial pathogens and their mammalian hosts. Changes in iron availability and distribution have significant effects on pathogen virulence and on the immune response to infection. Our previously published data shows that, during the first 24 hours of life, full-term neonates have reduced overall serum iron. Transferrin saturation decreases rapidly from 45% in cord blood to ~20% by six hours post-delivery.

Methods: To study neonatal nutritional immunity and its role in neonatal susceptibility to infection, we will conduct an observational study on 300 full-term normal birth weight (FTB+NBW), 50 preterm normal birth weight (PTB+NBW), 50 preterm low birth weight (PTB+LBW) and 50 full-term low birth weight (FTB+LBW), vaginally-delivered neonates born at Kanifing General Hospital, The Gambia. We will characterize and quantify iron-related nutritional immunity during the early neonatal period and use *ex vivo* sentinel bacterial growth assays to assess how differences in serum iron affect bacterial growth. Blood samples will be collected from the umbilical cord (arterial and venous) and at serial time points from the neonates over the first week of life.

Discussion: Currently, little is known about nutritional immunity in neonates. In this study, we will increase understanding of how nutritional immunity may protect neonates from infection during the first critical days of life by limiting the pathogenicity and virulence of neonatal sepsis causing organisms by reducing the availability of iron.

Open Peer Review

Approval Status

	1	2
version 2 (revision) 15 Oct 2019		
version 1 21 May 2019	 view	 view
1. Deborah Stefanova , ETH Zurich, Zurich, Switzerland		
2. Veena Sangkhae , University of California, Los Angeles (UCLA), Los Angeles, USA		
Any reports and responses or comments on the article can be found at the end of the article.		

Additionally, we will investigate the hypothesis that this protective mechanism may not be activated in preterm and low birth weight neonates, potentially putting these babies at an enhanced risk of neonatal infection.

Trial registration: clinicaltrials.gov ([NCT03353051](https://clinicaltrials.gov/ct2/show/study/NCT03353051)) 27/11/2017

Keywords

Nutritional Immunity, Host-Pathogen Interaction, Hepcidin, Neonates, Hypoferremia, Transferrin, The Gambia, Sub-Saharan Africa

Corresponding author: Carla Cerami (ccerami@mrc.gm)

Author roles: **Cross JH:** Data Curation, Formal Analysis, Investigation, Project Administration, Writing – Original Draft Preparation, Writing – Review & Editing; **Jarjou O:** Investigation, Project Administration, Supervision, Writing – Review & Editing; **Mohammed NI:** Formal Analysis, Writing – Review & Editing; **Prentice AM:** Conceptualization, Formal Analysis, Writing – Review & Editing; **Cerami C:** Conceptualization, Data Curation, Formal Analysis, Funding Acquisition, Investigation, Methodology, Project Administration, Resources, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: This study was supported by the Bill & Melinda Gates Foundation [OPP1152353].

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2019 Cross JH *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Cross JH, Jarjou O, Mohammed NI *et al.* **Neonatal iron distribution and infection susceptibility in full term, preterm and low birthweight babies in urban Gambia: study protocol for an observational study.** [version 2; peer review: 2 approved] Gates Open Research 2019, 3:1469 <https://doi.org/10.12688/gatesopenres.12963.2>

First published: 21 May 2019, 3:1469 <https://doi.org/10.12688/gatesopenres.12963.1>

REVISED Amendments from Version 1

This version has been edited based on the suggestions and questions of the two reviewers. We have addressed concerns about the timing of neonatal vaccinations and more methodological details have been added.

Any further responses from the reviewers can be found at the end of the article

Abbreviations

PTB = Preterm birth
 FTB = Fullterm birth
 LBW = Low birthweight
 NBW = Normal birthweight
 WHO = World Health Organisation
 TSAT = Transferrin saturation
 MDG = Millennium development goal
 GBS = Group B *Streptococci*
 EONS = Early onset neonatal sepsis
 YICSS = Young Infants Clinical Signs Studies
 KGH = Kanifing General Hospital
 MRCG = Medical Research Council Unit The Gambia at LSHTM
 KMC = Kanifing Municipal Council
 UIBC = Unbound iron-binding capacity
 IL6 = Interleukin 6
 IL22 = Interleukin 22
 sTfR = Soluble transferrin receptor
 CRP = C-reactive protein
 AGP = Alpha 1-acid glycoprotein
 HIV = Human immunodeficiency virus
 TB = Tuberculosis
 EDTA = Ethylenediaminetetraacetic acid
 V1 = Venous bleed 1
 V2 = Venous bleed 2
 IM = Intramuscular
 ELISA = Enzyme-linked immunosorbent assay
 ID = Identification
 CRF = Case report form
 eCRF = Electronic case report form
 ANOVA = Analysis of variance
 IDE = Integrated development environment
 CyTOF = Cytometry by time of flight
 STAT3 = Signal transducer and activator of transcription 3
 TLR = Toll-like receptor
 SOP = Standard operating procedure
 OD = Optical density
 WBC = White blood cell
 LPS = Lipopolysaccharide

Introduction**Neonatal infections – challenges in low-income settings**

Neonatal infection is the third largest cause of death in children under-five worldwide and is an ongoing major global public health challenge (Sustainable Development Goal 3.2)¹. Between 1990 and 2016 maternal and under-five child mortality has decreased by half². However, the proportion of neonatal deaths among under-five deaths increased from 37% (1990) to 44% (2013)^{3,4}. Today, approximately 2.8 million children die annually during the neonatal period – the first 28 days of life. Of these, 73% die within the first six days of life³. An increasing proportion of child deaths are in sub-Saharan Africa⁵, with 60–80% of newborn deaths occurring in low birthweight (LBW) neonates (<2500g at birth)⁶. 95% of all LBW neonates are born in low-income countries⁷. However, the situation is likely to be worse than documented, as neonatal deaths in developing countries are commonly under reported and the records commonly contain errors^{8,9}. It is estimated that about one third of deaths in the first month of life, are caused by infections including bacterial sepsis, meningitis, pneumonia, neonatal tetanus, and diarrhoea¹⁰.

Evidence is lacking on the aetiology of neonatal infections in developing countries, especially from community settings^{11,12}. However, the limited data suggests that *Klebsiella* species, *Escherichia coli*, and *Staphylococcus aureus* are common causes of early onset sepsis (EONS)^{13–15}. The available antibiotic susceptibility data suggests that pathogens associated with neonatal sepsis in developing countries are often resistant to WHO-recommended empiric antibiotics^{13,16}. Antibiotic resistance has emerged with potency over the last few decades due to a multitude of complex reasons. Antibiotic overuse, inappropriate prescribing, inadequate diagnostics, extensive agricultural use, availability of few new antibiotics, and the ease of transportation of resistant bacteria are among the factors contributing to the rise. Equally, bacteria have the ability to rapidly mutate (with or without drug selection pressure) and horizontally transfer genetic material between species (i.e. non-human pathogens) of bacteria^{17,18}. Neonates are particularly at risk from antibiotic resistant organisms because they generally succumb before alternative antibiotic regimes can be tried.

Diagnosis of neonatal sepsis with high specificity remains challenging in developing countries. A widely used tool developed by the World Health Organization Young Infants Clinical Signs Studies (YICSS), which includes seven clinical signs to aid diagnosis, has only a 85% sensitivity and 75% specificity for severe bacterial infection during the first week of life¹⁹. Microbiological identification of a pathogen isolated from blood cultures often has higher specificity, but microbiological laboratory facilities are frequently lacking in low-income settings¹⁹. With this all in mind, there is an immediate need to improve our understanding of neonatal blood-borne infections and develop novel therapies that could enhance immunological protection possibly via boosting innate immune mechanisms.

Nutritional immunity

Iron is critical for the human host and most pathogens. Iron is one of the most important factors in the host-pathogen battle

for resources. Bacteria and other pathogens have evolved a wide variety of mechanisms to acquire iron from the nutrient rich host (e.g. siderophores and iron specific channels)²⁰ to aid growth and virulence, with a number of iron acquisition genes concentrated on high pathogenicity islands²¹.

Nutritional immunity describes the normal physiological innate processes used by the host to combat infection by limiting nutrient availability. Key among these processes is the ability to rapidly decrease the circulating concentration of iron (and other transition metals) in response to an infection²². The hypoferremia of inflammation is mediated by the hormone, hepcidin. Research completed in 2000–2001 by three independent research groups led to the discovery of the hepcidin hormone, and the important function it plays in many aspects of iron metabolism^{23–25}. Hepcidin is now understood to be the master regulator of iron homeostasis. Unlike any other micronutrient, iron is regulated by a hormone that responds to both infection and nutritional status. The host inflammatory mediators, IL6²⁶, IL22²⁷ and Type 1 interferon²⁸, have been found to increase transcription of hepcidin through several Toll-like receptor (TLR) ligands²⁹ and STAT3 signalling^{30,31} resulting in decreased systemic iron concentrations in the circulation. This multifaceted mechanism limits nutrient availability to extracellular invading microorganisms³². The system is well documented in mouse models^{33–35}, but less so in human studies. However, it is clear that humans with excessive levels of serum iron (e.g. due to hemochromatosis) are predisposed to infection with iron-dependent species of bacteria^{36,37}.

Neonatal hypoferremia

Although iron metabolism in adults and older children is well studied, the kinetics of iron handling in the early neonatal period, a time of intense physiological change, are poorly understood³⁸. Childbirth results in a neonate moving from a semi-allogeneic, protected and nearly sterile environment to one that is abundant in a diverse array of microbes. The delivery process is the initial focal point for the mass bacterial colonisation of the skin and gastrointestinal tract of the neonate^{39,40}. Neonates are known to have very low levels of immunological memory and possess an immature immune system⁴¹. Post-natal iron metabolism in neonates is controlled by an array of different signals, such as hypoxia, erythropoietic drive, maternal and foetal iron stores⁴². A number of studies have investigated serum iron, transferrin saturation (TSAT), ferritin and haemoglobin levels at the time of birth using cord blood as a proxy for early neonatal blood^{43,44}. A recent prospective study showed neonates born preterm compared to early-term had higher serum iron concentrations in umbilical blood, which was inversely correlated with levels of serum hepcidin⁴⁵. A similar study has also shown that small-for-gestational-age neonates and neonates born by elective caesarean have lower levels of hepcidin⁴⁴. Previous work has shown that serum iron and TSAT decreases between birth and the first 6–12 hours postpartum in full term, healthy vaginally delivered newborns^{46,47}.

The study described here will shed light on the effects of prematurity and birthweight on body iron distribution immediately after birth and during the first week of life. Free ferric and ferrous iron (i.e. transferrin bound iron), haem-based iron molecules and their chaperone proteins (haem-hemopexin and haemoglobin-haptoglobin) will also be investigated.

Study objectives

The primary study objective is to characterize in detail how full term, preterm and low birthweight neonates modulate serum iron in the first 24 hours of life. We hypothesize that premature and/or low birthweight babies have a defect in their ability to sequester iron at 6–24 hours after birth in comparison to full term neonates with normal birthweight.

The secondary objectives are:

- I. Characterise how iron metabolism, handling and recycling differs between full term, preterm and low birthweight neonates at birth and during the first 24 hours of life.
- II. Describe iron metabolism, handling and recycling in full term neonates at birth and during the first 7 days of life.
- III. Determine if sera from preterm and low birthweight neonates supports a greater level of *ex-vivo* growth of microorganisms that are common causes of neonatal sepsis in Africa and The Gambia (*Staphylococcus aureus*, *Klebsiella pneumoniae*, *Escherichia coli*, Group B *Streptococcus*, *Streptococcus pneumoniae* and *Salmonella enterica* serovar Typhimurium (*S. Typhimurium* hereafter)) in comparison to sera from full term, normal birthweight neonates.
- IV. Characterize frequencies and functionality of neutrophils, monocytes, dendritic cells, NK cells, B cells and T cells (D8 and CD4) in cord blood from full term, premature and low birthweight neonates.

Protocol

Study site

Study participants will be recruited from Kanifing General Hospital (formally Serrekunda General Hospital), in the Kanifing region of The Gambia, West Africa. Serrekunda is a large town, forming a peri-urban area with a population of around 340,000, and is 13km to the southwest of the capital, Banjul. Serrekunda was originally made up of nine villages that have merged into a sprawling urban area. Annually, Kanifing General Hospital (KGH) provides antenatal care to 500–700 pregnant mothers. Mothers receiving antenatal care at other local health-care facilities increase the total number of births at the hospital to 3500–4500 per year. The percentage of these that are live, low birthweight neonates (<2.5kg) is approximately 10%. Specimen samples will be subjected to primary processing on-site at KGH, followed by transport to Medical Research Council Unit The Gambia at LSHTM (MRCG) for storage and analysis.

Participants

In total, 450 healthy newly born neonates will be identified during delivery at the Kanifing General Hospital Maternity Ward (Figure 1) starting in July 2017. Pregnant mothers must be over the age of eighteen years. After informed consent is obtained, neonates who meet the inclusion criteria will be enrolled into the study. For inclusion in the study, neonates must be healthy, medically stable, greater than 32 weeks gestational age and weigh more than 2000g. To be considered preterm (PTB) the neonates will be < 37 weeks gestational age (assessed by New Ballard Score⁴⁸) and ≥ 32 weeks gestational age. All neonates




Figure 1. Main study flow chart of all study procedures and exclusion criteria. Group A will contain neonates characterised by preterm birth and low birthweight (PTB+LBW); Group B will contain neonates characterised by preterm birth and normal birthweight (PTB+NBW); Group C will contain neonates characterised by full term birth and low birthweight (FTB+LBW); Groups D1, D2 and D3 will all contain babies characterised by full term birth and normal birthweight (FTB+NBW). In this study, preterm is defined <37 weeks gestation and low birthweight is <2500g. Exclusion criteria (a): Father refused, mother refused, family/escort refused, communication not possible or mother with severe disabilities. Exclusion criteria (b): Antibiotics or antimalarials given before delivery (<24 hours), referred to tertiary level health facility, absconded, known HIV-positive, severe pre-eclampsia, receiving TB treatment, antepartum haemorrhage, recent blood transfusion (within the last month), no foetal heartbeat, mother <18 years, refusal, recruited to another study and emergency caesarean section. Exclusion criteria (y): Recruited to another study on-site, refusal, blood transfusion given in labour, antibiotics or antimalarials given during labour, neonate requires resuscitation (1 min APGAR), neonatal weight <2000g, neonate born breech, neonate born via vacuum delivery, neonate born caesarean section, foetal stillbirth, macerated stillbirth and major congenital malformations. Exclusion criteria (d): Failed cord blood collection (serum tubes), failed cord blood collection (EDTA), cord blood processed >6 hours, neonate requires resuscitation (10 min APGAR), absconded and route 2B refusal. Exclusion criteria (e): Mother birth check refusal, father birth check refusal, family escort birth check refusal, mother <18 years, recruited to another study on-site, antibiotics or antimalarials given to mother before delivery (<24 hours), neonate has had surgery, neonates sibling twin was recruited, neonate given antibiotics (other than tetracycline eye ointment), neonate given iron supplementation, neonatal sickness (tone, activity, feeding, heart rate, respiratory rate, abnormal anterior fontanelle), neonatal temperature (<36.5°C or >37.5°C), major congenital malformations (neonate), New Ballard Score (<32 weeks), failed V1 (serum), failed V1 (EDTA), failed V1 (both EDTA and serum), mother V1 bleed refusal, father V1 bleed refusal, and family/escort V1 bleed refusal. Exclusion criteria (z): neonatal sickness (tone, activity, feeding, heart rate, respiratory rate, abnormal anterior fontanelle), neonatal temperature (<36.5°C or >37.5°C), neonate has had surgery, neonate given antibiotics (other than tetracycline eye ointment), neonate given iron supplementation, failed V2 bleed, Mother community/V2 bleed refusal, father community/V2 bleed refusal, and family community/V2 bleed refusal.

with a gestational age ≥ 37 weeks will be considered full term (FTB). To be considered low birthweight (LBW) the neonates will weigh < 2500 g. All neonates weighing ≥ 2500 g will be considered normal birthweight (NBW).

The study groups are:

Group A (PTB+LBW): Neonates who are both preterm and low birthweight.

Group B (PTB+NBW): Neonates who are preterm and normal birthweight.

Group C (FTB+LBW): Neonates who are full term but low birthweight.

Group D (FTB+NBW): Neonates who are full term and normal birthweight.

In addition to the main study, 300 FTB neonates of the 450 neonates will also be included into a sub-study, which aims to describe serum iron markers in full term babies (Group D, FTB+NBW only) over the first week of life.

Study design

This is a proof-of-concept, observational cohort study (Groups A, B, C and D) with an embedded short prospective cohort study (Group D divided into D1, D2 and D3).

Entry evaluation

Consent and enrolment. There are two routes into the study enrolment (Figure 2). Pregnant mothers who are receiving antenatal care on-site at KGH, will be approached at an antenatal visit and voluntarily sensitised to the study requirements and protocol (Route 1). Pregnant women, who are sensitised will not be required at that point to give written or verbal consent. This group will be provided with study information sheets and encouraged to discuss study participation with their family. When the pregnant woman returns to KGH Maternity Ward to deliver (some mothers will choose to deliver at other healthcare facilities), she will be asked to read the full study information sheet (or have it read to her by a study nurse if she is not literate) and provide formal written consent to the study involvement for their neonate (see Extended data^{49–51}).

Route 2 will provide an alternative route of enrolment for pregnant mothers, that would like their neonate to be part of the study but have been receiving antenatal care at another facility before delivering at KGH maternity ward. In route 2, healthy, pregnant women will enter the KGH ward to deliver and will be approached to provide written formal consent to umbilical cord blood collection and storage only. No testing or laboratory processes will be conducted on their sample, until full study consent is gained post-delivery. The cord blood sample will be stored at 4°C (within the maternity ward), until the mother's pain and discomfort subside. Mothers will be approached 2–6 hours post-delivery on a one-to-one basis by our research clinician. The research clinician will independently verify if the mother displays normal psychological function and is not under distress before the consenting process begins. At this point, the mother and/or father will be invited to provide written formal consent on full study enrolment. If, at this point, mother and/or father refuse full study consent post-delivery, the previously collected

personal information and umbilical cord sample will be safely discarded. Good clinical practise will be followed at all times.

Pre-delivery screening

In both Route 1 and Route 2 enrolment, mothers must provide written consent before assessment of personal information (antenatal card) and questioning can begin. After consenting, mothers will be asked for their demographic information and their personal contact details. Pregnant mothers will be excluded from the study if they are below the age of 18 years, have no foetal heartbeat detected upon admission, known to be HIV-positive, in receipt of *Mycobacterium tuberculosis* therapy, taken antibiotics in the last 24 hours, had a blood transfusion in the last month, suffering from severe pre-eclampsia or antepartum haemorrhage, or in another research study. Mothers can refuse to be part of the study at any stage of the study protocol. Pregnant women that are referred at this point to a tertiary level healthcare facility, will be excluded from the study.

Delivery procedures, post-delivery screening and umbilical cord blood collection

Delivery procedures and screening. Study nurses will assist clinical KGH maternity ward staff in the delivery process and collect data via electronic case report form (eCRF) on their designated study tablets. Neonates will be excluded at the delivery stage of the study for the following reasons: major congenital malformations (not including polydactyly), blood transfusions given to mother or neonate, severe birth asphyxia (requiring resuscitation), neonates born via breech, vacuum or via caesarean section, or a birthweight < 2000 g. After the delivery stage of the study protocol, neonates can be excluded from the study following the detection of infection or illness (information gained from full blood count analysis or review of systems). Neonates will also be removed from the study protocol, if medication is given (not including intramuscular vitamin K, tetracycline eye ointment or any immunisations). All medication that is given to mothers and neonates will be recorded. Mothers will be able to refuse study participation at any stage. Mothers that deliver multiple newborns will only be invited to consent and enrol one of their neonates into the study.

Umbilical cord blood collection. Once the neonate is fully delivered, one-minute delayed cord clamping will be used (following World Health Organisation (WHO) policy⁵²). During the one-minute delay, the one-minute APGAR score will be conducted. If the neonate requires resuscitation, the neonate will be excluded from the study. After the umbilical cord has been removed and cleaned, a trained study nurse will identify the umbilical arteries and the umbilical vein. Blood will be collected from both. The tubes will be placed in the cool box for 1–6 hours before transfer to the study laboratory for primary processing. If the mother is enrolled by route 2, the mother will be asked to provide written consent to full study recruitment before the sample is sent for primary laboratory processing. The time between the collection and the processing of blood samples will be recorded and analysed.

Hospital assessment and 1st venous blood draw

Hospital health assessment (study recruitment and group allocation). At 6–24 hours post-delivery, recruited mothers




Figure 2. Neolnnate Study enrolment route and blood draw design. Group A contains neonates characterised by preterm birth and low birthweight (PTB+LBW); Group B contains neonates characterised by preterm birth and normal birthweight (PTB+NBW); Group C contains neonates characterised by full term birth and low birthweight (FTB+LBW); Groups D1, D2 and D3 all contain babies characterised by full term birth and normal birthweight (FTB+NBW).

and their neonates will be invited to a private consultation with the study research clinician. Further demographic data will be collected, along with a photograph of the antenatal card to gather gestational age data (fundal height, last menstrual period and ultrasound), mother's last haemoglobin level before delivery (dated), known sickle cell status, neonate immunisations, and medication given to the mother (pre, during and post-delivery) and the neonate. A complete review of systems of the mother and neonate plus anthropometric data on the newborn will then be collected. Neuromuscular and physical maturation of each neonate will be assessed using the New Ballard Score⁴⁸.

Neonates will be excluded if they score less than 32 weeks of gestation. From this assessment, the neonate will be assigned to a specific study group. If the neonate is allocated to the Group D (FTB+NBW) group, the neonate will be allocated to a randomised bleed group (≥ 24 hours - < 80 hours (Group D1); ≥ 80 hours - < 136 hours (Group D2); and ≥ 136 - < 192 hours (Group D3). Failure to meet the inclusion criteria at this stage of the study protocol, will result in exclusion from the study.

According to current practice, at-birth vaccination of neonates at Kanifing General Hospital (The Gambia), does not occur until a later time point in the first week of life due to social and logistical reasons. However, mothers will still be asked whether the neonate has been vaccinated prior to the health assessment before the 1st venous bleed takes place. The answers will be recorded and analysed.

1st venous blood draw (all neonates). A blood sample will be collected from all neonates that have passed the inclusion criteria in the hospital health assessment. Immediately after the health assessment, a venous blood draw will be performed (6–24 hours post-delivery). PTB and/or LBW neonates will donate 2ml of venous blood. FTB+NBW neonates will donate 3.5ml of venous blood. All samples will reach the laboratory within three hours post collection for primary processing.

Community health assessment and 2nd venous blood draw
Community health assessment. Study nurses will visit all mothers or enrolled neonates at their homes at least once. At that visit, a physical examination of the neonate will be completed. The following information will also be collected: neonatal immunisation history (date, time and type), a complete review of systems of the mother and baby, and any medication given to the mother or neonate since delivery. Mothers will also be provided with health education and study contact details (should the neonate become unwell). The effect of vaccination on iron and inflammatory parameters in the first week of life will be analysed as part of the formal data analysis plan.

2nd venous blood draw Group D (FTB+NBW) only. At this point, if the mother and neonate are deemed to have passed the screening process and the neonate is in Group D, then the neonate will have its second and last venous blood draw (3.5ml). All samples will reach the laboratory within three hours post collection for primary processing.

Laboratory evaluations

Blood samples. The processing of samples will be conducted 1–6 hours after collection to allow serum samples to coagulate and to allow mothers admitted via route 2 to give written consent. On arrival to the laboratory, whole blood samples in 4.5ml Sarstedt S-Monovette K3E (SARSTEDT AG & Co. KG, Germany) will be inverted five times and assessed for a full haematology panel using a Medonic M20M GP (Boule Diagnostics, Spanga, Sweden). The remaining whole blood sample will be aliquoted into 2ml Sarstedt micro tubes (SARSTEDT AG & Co. KG, Germany) and frozen at -20°C . Glucose-6-phosphate dehydrogenase deficiency testing (R&D Diagnostics Limited, Papagos, Greece) and sickle trait will be conducted at the end of the recruitment period of the study.

The Sarstedt S-Monovette Serum-Gel blood collection tube (SARSTEDT AG & Co. KG, Germany) will be centrifuged at 3500rpm for 10 mins using an Eppendorf Centrifuge 5702 (Eppendorf, Germany). Serum will be aliquoted into 2ml Sarstedt micro tubes (SARSTEDT AG & Co. KG, Germany), boxed and labelled before being stored at -20°C until after the recruitment period. The laboratory analysis of all serum samples will be conducted as one batch. All serum samples collected will be assessed by ELISA for the following: IL6, IL22, free haem, hepcidin, hemopexin, lipocalin-2, lactoferrin, and foetal haemoglobin. DRG Hepcidin 25 (bioactive) HS ELISA (EIA-5782) (dynamic range: 0.135 - 81 ng/mL), made by DRG Instruments GmbH, Germany, will be used to measure serum hepcidin. Additionally, serum ferritin, serum iron, UIBC, soluble transferrin receptor (sTfR), transferrin, C-reactive protein (CRP), haptoglobin, and alpha 1-acid glycoprotein (AGP) will be assessed using a fully automated biochemistry analyser (Cobas Integra 400 plus). Furthermore, umbilical WBC will be processed and analysed for exploratory secondary analysis 4.

Bacterial growth assays. *Ex vivo* growth of bacteria (including clinical and laboratory isolates of *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Escherichia coli*, *Enterobacter* spp., *Enterococcus* spp., and *Salmonella* Typhimurium) in a 1:1 mixture of participant serum and Iscove's Modified Dulbecco's Medium (IMDM, Invitrogen) as in Cross *et al.* (2015)⁵³ will be performed.

Study outcomes

The primary outcome variables will be TSAT (transferrin saturation) and serum iron.

The secondary outcome variables will be hepcidin; hemopexin; haptoglobin; IL22; free serum haem and haemoglobin; foetal haemoglobin; lactoferrin; lipocalin-2; IL6; C-reactive protein; alpha-1-acid glycoprotein; transferrin concentration; soluble transferrin receptor; unbound iron-binding capacity; ferritin; haemoglobin; WBCs types and numbers in cord blood samples and *ex vivo* bacterial growth.

Data entry, handling, storage and security

All protocol-required field data will be captured electronically on an electronic eCRF or a paper case report form (CRF)

that will be completed for each included participant. After giving written consent the pregnant women will be given a study identification number, which will be used in all future datasets for subject anonymity. Field data will be collected verbally and from antenatal cards by study nurses. Collected data will be entered in real time using eCRFs developed on top of a REDCap (Research Electronic Data Capture) database and published on Samsung Galaxy Tab 3 SM-T111 handheld devices. Collected data will be transported to the database via a direct secure connection over the 4G mobile network. Laboratory related data will be extracted directly from laboratory equipment and uploaded to the database. Any data collected on the paper format will be double entered by a trained data entry clerk. The local co-investigator will review all forms and identify any errors prior to data entry or to marking data as complete. The study data will also be validated through automated and manual validation methods implemented in the study database application system. The study database will be custom-developed. All paper CRF will be stored in a locked file archive. Electronic data will be stored on the local dedicated server maintained at MRCG. The study will be conducted in compliance with Good Clinical Practice. Study personal security measures will include controlled access limited to authorised users only, physical security, remove identifiable information (anonymization), avoidance of third-party cloud storage and password protection.

Sample size and power

This study will target recruitment of 150 “exposed” neonates which will include a target of 50 neonates in each Group A, B and C. 300 neonates will be recruited for Group D (“unexposed”). The study will have constraints from time, budget, loss to follow up, haemolysis during sample collection, insufficient blood volume and the distribution of new births in each group at the Kanifing General Hospital.

Based on this, we have run simulations (Stata/IC 15.1) to calculate the power to detect a range of differences comparing groups for example Groups D and A with respect to the primary outcomes TSAT and serum iron. We did not calculate power for the secondary outcomes, which are considered exploratory. The simulation was run using a linear regression model assuming a lognormal distribution for the response variables TSAT and serum iron levels 6–24 hours after birth. Data from a previous study (Prentice S, personal communication) was used to obtain mean and SD estimates for TSAT and serum iron both at baseline and 6–24 hours after birth. The predictor variables were the Groups (A–D) with Group D as the reference. The model was adjusted for the baseline (cord blood levels). We also examined the power assuming a normal distribution for TSAT (i.e. without log transformation). The significance level considered was 0.05 and the simulation was run for 100000 iterations. This process was repeated for the following four different sample size scenarios which we refer to as *N1*, *N2*, *N3* and *N4* respectively:

- N1*) Group A=Group B=Group C=50 neonates
- N2*) Group A=Group B=25 neonates and Group C=50 neonates
- N3*) Group A=Group B=10 neonates and Group C=50 neonates
- N4*) Group A=Group B=50 neonates and Group C=10 neonates

For all the above four cases, *D*=300.

The simulation results for the baseline adjusted model with log transformation show that for sample size scenario *N1*, the minimum mean differences that can be detected with 80% power were about 4% and 2.5 $\mu\text{mol/L}$ for TSAT and serum iron respectively (Figure 3A and 3B). These correspond to effect sizes of 0.35 and 0.39 respectively. The power drops substantially if smaller numbers were to be recruited as in scenarios *N2* (*A*=*B*=25) and *N3* (*A*=*B*=10). Under *N2* and *N3*, the minimum mean differences that can be detected with 80% would increase to about 5.8% and 9.1% for TSAT (Figure 3A) and 3.3 $\mu\text{mol/L}$ and 5 $\mu\text{mol/L}$ for serum iron (Figure 3B). The results for scenario *N4* can be considered as subset of *N1*–*N3* by rearranging Groups A, B and C.

Statistical analysis

The primary research objective is to examine if preterm and/or low birthweight neonates (“Exposed”) have a reduced ability to sequester iron at 6–24 hours after birth in comparison to full term neonates with normal birthweight (“Unexposed”)?

We hypothesize that FTB+NBW (Group D) neonates on average will have lower values of TSAT and serum iron compared to “Exposed” (PTB or LBW babies) (Figure 4). Initially, we will analyse all “Exposed” (Groups A+B+C) vs “Unexposed” (Group D). Each neonate will be further classified by his or her gestational age (premature vs. full term) and birthweight (low vs. normal) in a 2x2 table (Table 1). Linear regression models will be used in order to evaluate the difference in mean between each Group A–C and D; that is where *D* will be the reference group. TSAT and serum iron levels will be log transformed before fitting the models (if necessary). Both the unadjusted and adjusted (for the cord blood level) mean differences together with the 95% CI will be calculated.

In the second stage of analysis, we will assess the effect of potential confounding variables using the regression models. Covariates to be considered include the specific time of measurement, demographic and health variables. The time effect may not be linear, and this will be investigated in the further regression models. To reduce the effects of multiple testing, data analysis will be driven by a predefined primary study hypothesis. Any exploratory analyses conducted (in the absence of predefined study hypotheses) will be considered hypothesis-generating, rather than confirmatory. In order to reduce the levels of missing and inaccurately entered data into the database, all clinical, demographic and laboratory data will be entered in real time via electronic data capture, with automated and manual validation methods implemented. The study design does not provide for the recruitment of equal numbers of subjects in each month of the year (or during the dry vs wet seasons). The Gambia has a higher birth rate during the months of September–December in comparison to other months⁵⁴.

In order to remove this potential source of bias, we will adjust for month of birth and/or season in the regression analysis. If the missing data rates is more than 5%, we will consider imputation. The follow-up duration is relatively short. Thus, we expect little bias from loss to follow-up. If loss to follow-up rate is considerably different between groups, we will perform sensitivity analyses to examine the robustness of results. We will also




Figure 3. Estimated power to detect a given difference between Groups A vs D based on simulation using a linear regression model adjusted for baseline for three sample size scenarios. N1 (Group A=Group B=Group C=50 neonates); N2 (Group A=Group B=25 neonates and Group C=50 neonates); N3 (Group A=Group B=10 neonates and Group C=50 neonates); N4 (Group A=Group B=50 neonates and Group C=10 neonates).




Figure 4. An example of hypothetical scenario for TSAT values between the groups to be compared. In this example: (i) Time 0 refers to average cord blood levels (ii) Time 6–24 refers to the mean level in the 6–24 hour period after birth. (iii) T1, T2, represent TSAT in 1 and 2 above and $\Delta T = T2 - T1$ for full term, normal birthweight (Group D) (iv.) T1', T2' and $\Delta T' = T2' - T1'$ same as above but for the premature, low birthweight (Group A). Hypothesis: $H_0: T2 = T2'$ vs. $H_A: T2 \neq T2'$.

consider sensitivity analysis fitting a multivariate regression model where the main outcomes of interest (including TSAT, serum iron and hepcidin) will be jointly regressed to the same set of predictors.

Table 1. Four combinations in total for exposure: a: Pre, Low; b: Pre, Normal; c: Full, Low and d: Full, Normal.

		Birthweight (BW)	
		Low	Normal
Term	Pre	A	B
	Full	C	D

The analysis for the secondary objectives are described below:

I. Characterise how iron metabolism, handling and recycling differs between full term, preterm and low birthweight neonates at birth and during the first 24 hours of life.

A similar strategy will be used as for the primary objective. Regression modelling will be used to evaluate the difference in means between each Group A–C and D; D will be the reference (“Unexposed”) group. The effects of potential confounding variables will also be assessed using further regression modelling.

II. Describe iron metabolism, handling and recycling in full term neonates at birth and during the first 7 days of life.

Analysis of the longitudinal data will involve generalised estimating equations incorporating time of measurement. We will include spline terms at each time point to evaluate the change in

the outcomes (all primary and secondary outcome parameters) over time during the transition period from cord to 24–79; 80–135; 136–192 hours after birth. Note that this will only include data collected from Group D neonates and will not be a comparison between Groups A–C and D neonates.

III. Determine if sera from preterm and low birthweight neonates supports a greater level of *ex-vivo* growth of microorganisms that are common causes of neonatal sepsis in Africa and The Gambia (*Staphylococcus aureus*, *Klebsiella pneumoniae*, *Escherichia coli*, *Enterobacter* spp., *Enterococcus* spp., and *S. Typhimurium*) in comparison to sera from FTB+NBW neonates.

The bacterial growth will be analysed in a similar method as described in Cross *et al.* (2015)⁵³ in order to determine if changes in iron availability modulate the growth. Growth assays will be fitted to a standard form of the logistic equation:

$$N_t = \frac{K}{1 + \left(\frac{K - N_0}{N_0}\right)e^{-rt}}$$

Here, the population size at the beginning of the growth curve is given by N_0 . The carrying capacity is given by K . The intrinsic growth rate of the population is r . We will generate the best fitting values of K , r and N_0 for the growth curve data. Additionally, for each bacterium, we compare the time at which the population density reaches $\frac{1}{2}K$ (inflection point), the fastest possible generation time (doubling time) and the area under the logistic curve obtained by taking the integral of the logistic equation. This will be used to assess growth curves from different sample types (Cord vs V1) and between the four study groups.

IV. Characterize frequencies and functionality of neutrophils, monocytes, dendritic cells, NK cells, B cells, T cells (D8 and CD4) in cord blood from full term, premature and low birthweight neonates.

Exploratory analysis will be conducted using linear regressions modelling.

Statistical analyses will be performed using [STATA](#) (StataCorp. 2017. Stata Statistical Software: Release 15. College Station, TX: StataCorp LLC); [R](#) (R Foundation for Statistical Computing, Vienna, Austria.) and [Data Desk](#) (Data Description Inc Ithaca NY). All files used will have an accompanying data dictionary. Annotated STATA do-files or R files will be used to describe any data transformations and statistical tests used.

Dissemination of findings

The study results will be published in relevant peer-reviewed journals and key findings will be presented at international scientific meetings. Data sharing will be in agreement with the sponsor policy on research data sharing and with the Bill & Melinda Gates Foundation Global Access requirements.

Study status

The study is in the data collection phase.

Discussion

Humans and bacteria are involved in an on-going tug of war over iron. Each side has evolved complicated and varied iron-acquisition mechanisms in an effort to turn the tide of war in their own favour⁵⁵. Nutritional immunity describes the processes by which the human host tries to starve invading organisms of nutrients, especially iron.

This study aims to determine if premature and low birthweight babies have a defect in their ability to sequester iron during the first 24 hours of life. The study design will produce a detailed and extensive picture of iron metabolism in neonates. To our knowledge, no other study has tried to analyse such a large and diverse collection of iron and infection variables in neonates born in Sub Saharan Africa. The study will enrol subjects who are all at an increased risk of neonatal infection, and subsequent sepsis and death.

A potential limitation of this study is the inadequacy of using the New Ballard Score as the only method of gestational aging. Original and New Ballard Score are reported to overestimated gestational age compared to ultrasound and in particular, misclassify preterm infants as term newborns⁵⁶. Additionally, newborn clinical assessments as a whole, tend to underestimate gestational age in growth-restricted neonates⁵⁶. The gold standard of gestational aging is an ultrasound in the first trimester⁵⁷. However, this procedure is rarely correctly completed in this study population. If it is documented on the mother's antenatal records, care will be taken to record it. Limits of the study also include that HIV status, TB status and iron supplementation given are all gained from the antenatal records of the mother. Furthermore, antenatal records will not contain all information on medication given in every mothers' pregnancy. As a result, care will be made to extensively question participants mother's during verbal one-to-one consultation with our study research clinician.

In conclusion, our overarching study goal is to evaluate the likelihood that novel products designed to induce hypoferraemia (potentially via mini-hepcidins⁵⁸) may be useful in the future for the prevention of neonatal sepsis in high risk babies. This could be produced by a transient redistribution of iron away from the circulation, thus applying a bacteriostatic brake on any bacteria that have crossed into the baby's systemic circulation and hence boosting host survival in vulnerable newborns. We hope this may ultimately help reduce the use of antibiotics in maternal and neonatal wards worldwide.

Ethical approval

This study has been approved by The Gambia Government/MRC Joint Ethics Committee (no. SCC1525) and Ethics Committee of London School of Hygiene and Tropical Medicine (ref no.

14316). The study procedures will be explained to the neonate's mother/guardians orally or in writing. A neonate is only recruited into the study after the consent form has been signed/thumb printed by the mother/guardian.

This study was registered with clinicaltrials.gov ([NCT03353051](https://clinicaltrials.gov/ct2/show/study/NCT03353051)) on 27 November 2017.

Data availability

Underlying data

No data are associated with this article.

Extended data

Figshare: Cross *et al.* GatesOpen Research SCC1525v2__NeoInnate_Participant Info&Consent form Route 1. <https://doi.org/10.6084/m9.figshare.8069195.v4>⁴⁹

This project contains the following extended data:

- SCC1525v2__NeoInnate_Consent form Route 1_v3 Approved8Nov17.docx (Route 1 consent and information sheet)

Figshare: Cross *et al.* GatesOpenResearch SCC1525v2__NeoInnate_Consent form Route 2_Part 1_ (Umbilical Cord Blood Collection) - Labour Ward_v1.1-Approved 8Nov17. <https://doi.org/10.6084/m9.figshare.8069246.v1>⁵⁰

This project contains the following extended data:

- SCC1525v2__NeoInnate_Consent form Route 2_Part 1_ (UCB Collection) - Labour Ward_v1.1-Approved 8Nov17.docx (Route 2 consent and information sheet part 1)

Figshare: Cross *et al.* Gates Open Research SCC1525v2__NeoInnate_Consent form Route 2_Part 2_(Post-Delivery) - ANC Outside SGH v1-Approved 8Nov17. <https://doi.org/10.6084/m9.figshare.8069243.v1>⁵¹

This project contains the following extended data:

- SCC1525v2__NeoInnate_Consent form Route 2_Part 2_(Post-Delivery) - ANC Outside SGH v1-Approved 8Nov17.docx (Route 2 consent and information sheet part 2)

Data are available under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/) (CC-BY 4.0).

Acknowledgements

We thank Kanifing Municipal Council (KMC) and Kanifing General Hospital (KGH) for their support during the study.

References

1. WHO: **WHO | Every Newborn: an action plan to end preventable deaths**. WHO (World Health Organization), 2014. [Reference Source](#)
2. United Nations Children's Fund, World Health Organization, W. B. and U. N: **Levels & Trends in Child Mortality. Report 2017. Estimates developed by the UN Inter-agency Group for Child Mortality Estimation**. New York (NY): United Nations Children's Fund. Levels & Trends in Child Mortality. Report 2017. 2017. [Reference Source](#)
3. WHO, UNICEF: **UNICEF - Levels & Trends in Child Mortality. Rep.2014**, 2014. [Reference Source](#)
4. Lawn JE, Kinney MV, Black RE, *et al.*: **Newborn survival: a multi-country analysis of a decade of change**. *Health Policy Plan*. 2012; 27 Suppl 3: iii6–iii28. [PubMed Abstract](#) | [Publisher Full Text](#)
5. United Nations Inter-agency Group for Child Mortality Estimation (UN IGME): **United Nations Inter-agency Group for Child Mortality Estimation (UN IGME), 'Levels & Trends in Child Mortality: Report 2018, Estimates developed by the United Nations Inter-agency Group for Child Mortality Estimation'**. United Nations Children's Fund, New. [Reference Source](#)
6. World Health Organization: **Care of the preterm and/or low-birth-weight newborn**. [Updated 2017]. Accessed Dec 2018. [Reference Source](#)
7. UNICEF & WHO: **United Nations Children's Fund and World Health Organization, Low Birthweight: Country, regional and global estimates**. UNICEF, New York. 2004; 27. [Reference Source](#)
8. Oza S, Cousens SN, Lawn JE: **Estimation of daily risk of neonatal death, including the day of birth, in 186 countries in 2013: a vital-registration and modelling-based study**. *Lancet Glob Health*. 2014; 2(11): e635–e644. [PubMed Abstract](#) | [Publisher Full Text](#)
9. Hill K, Choi Y: **Neonatal mortality in the developing world**. *Demogr Res*. 2006; 14: 429–452. [Publisher Full Text](#)
10. Lawn JE, Cousens S, Zupan J, *et al.*: **4 million neonatal deaths: when? Where? Why?** *Lancet*. 2005; 365(9462): 891–900. [PubMed Abstract](#) | [Publisher Full Text](#)
11. Huynh BT, Padgett M, Garin B, *et al.*: **Burden of bacterial resistance among neonatal infections in low income countries: how convincing is the epidemiological evidence?** *BMC Infect Dis*. 2015; 15: 127. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
12. Saha SK, Schrag SJ, El Arifeen S, *et al.*: **Causes and incidence of community-acquired serious infections among young children in south Asia (ANISA): an observational cohort study**. *Lancet*. 2018; 392(10142): 145–159. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
13. Waters D, Jawad I, Ahmad A, *et al.*: **Aetiology of community-acquired neonatal sepsis in low and middle income countries**. *J Glob Health*. 2011; 1(2): 154–70. [PubMed Abstract](#) | [Free Full Text](#)
14. Simonsen KA, Anderson-Berry AL, Delair SF, *et al.*: **Early-onset neonatal sepsis**. *Clin Microbiol Rev*. 2014; 27(1): 21–47. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
15. Okomo U: **Neonatal Infections; a hospital-based study in The Gambia examining aetiology and associated maternal Colonisation**. London School of Hygiene & Tropical Medicine. 2018. [Publisher Full Text](#)
16. Lubell Y, Ashley EA, Turner C, *et al.*: **Susceptibility of community-acquired pathogens to antibiotics in Africa and Asia in neonates—an alarmingly short review**. *Trop Med Int Health*. 2011; 16(2): 145–151. [PubMed Abstract](#) | [Publisher Full Text](#)
17. Laxminarayan R, Duse A, Wattal C, *et al.*: **Antibiotic resistance—the need for global solutions**. *Lancet Infect Dis*. 2013; 13(12): 1057–1098. [PubMed Abstract](#) | [Publisher Full Text](#)
18. Davies J, Davies D: **Origins and evolution of antibiotic resistance**. *Microbiol Mol Biol Rev*. 2010; 74(3): 417–33. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
19. Young Infants Clinical Signs Study Group: **Clinical signs that predict severe illness in children under age 2 months: a multicentre study**. *Lancet*. 2008; 371(9607): 135–142. [PubMed Abstract](#) | [Publisher Full Text](#)
20. Caza M, Kronstad JW: **Shared and distinct mechanisms of iron acquisition by bacterial and fungal pathogens of humans**. *Front Cell Infect Microbiol*. 2013; 3: 80. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
21. Koczura R, Kaznowski A: **Occurrence of the *Yersinia* high-pathogenicity island**

- and iron uptake systems in clinical isolates of *Klebsiella pneumoniae*. *Microb Pathog*. 2003; **35**(5): 197–202.
[PubMed Abstract](#) | [Publisher Full Text](#)
22. Drakesmith H, Prentice AM: **Hepcidin and the iron-infection axis**. *Science*. 2012; **338**(6108): 768–772.
[PubMed Abstract](#) | [Publisher Full Text](#)
 23. Krause A, Neitz S, Mägert HJ, *et al.*: **LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity**. *FEBS Lett*. 2000; **480**(2–3): 147–50.
[PubMed Abstract](#) | [Publisher Full Text](#)
 24. Pigeon C, Ilyin G, Courselaud B, *et al.*: **A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload**. *J Biol Chem*. 2001; **276**(11): 7811–7819.
[PubMed Abstract](#) | [Publisher Full Text](#)
 25. Park CH, Valore EV, Waring AJ, *et al.*: **Hepcidin, a urinary antimicrobial peptide synthesized in the liver**. *J Biol Chem*. 2001; **276**(11): 7806–7810.
[PubMed Abstract](#) | [Publisher Full Text](#)
 26. Nemeth E, Rivera S, Gabayan V, *et al.*: **IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin**. *J Clin Invest*. 2004; **113**(9): 1271–1276.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 27. Armitage AE, Eddowes LA, Gileadi U, *et al.*: **Hepcidin regulation by innate immune and infectious stimuli**. *Blood*. 2011; **118**(15): 4129–39.
[PubMed Abstract](#) | [Publisher Full Text](#)
 28. Ryan JD, Altamura S, Devitt E, *et al.*: **Pegylated interferon- α induced hypoferremia is associated with the immediate response to treatment in hepatitis C**. *Hepatology*. 2012; **56**(2): 492–500.
[PubMed Abstract](#) | [Publisher Full Text](#)
 29. Peyssonnaud C, Zinkernagel AS, Datta V, *et al.*: **TLR4-dependent hepcidin expression by myeloid cells in response to bacterial pathogens**. *Blood*. 2006; **107**(9): 3727–32.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 30. Wrighting DM, Andrews NC: **Interleukin-6 induces hepcidin expression through STAT3**. *Blood*. 2006; **108**(9): 3204–3209.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 31. Verga Falzacappa MV, Vujic Spasic M, Kessler R, *et al.*: **STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation**. *Blood*. 2007; **109**(1): 353–358.
[PubMed Abstract](#) | [Publisher Full Text](#)
 32. Rodriguez R, Jung CL, Gabayan V, *et al.*: **Hepcidin induction by pathogens and pathogen-derived molecules is strongly dependent on interleukin-6**. *Infect Immun*. 2014; **82**(2): 745–52.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 33. Areses J, Jung G, Gabayan V, *et al.*: **Hepcidin-induced hypoferremia is a critical host defense mechanism against the siderophilic bacterium *Vibrio vulnificus***. *Cell Host Microbe*. 2015; **17**(1): 47–57.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 34. Michels KR, Zhang Z, Bettina AM, *et al.*: **Hepcidin-mediated iron sequestration protects against bacterial dissemination during pneumonia**. *JCI Insight*. 2017; **2**(6): e92002.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 35. Stefanova D, Raychev A, Areses J, *et al.*: **Endogenous hepcidin and its agonist mediate resistance to selected infections by clearing non-transferrin-bound iron**. *Blood*. 2017; **130**(3): 245–257.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 36. Frank KM, Schneewind O, Shieh WJ: **Investigation of a researcher's death due to septicemic plague**. *N Engl J Med*. 2011; **364**(26): 2563–2564.
[PubMed Abstract](#) | [Publisher Full Text](#)
 37. Khan FA, Fisher MA, Khakoo RA: **Association of hemochromatosis with infectious diseases: expanding spectrum**. *Int J Infect Dis*. 2007; **11**(6): 482–487.
[PubMed Abstract](#) | [Publisher Full Text](#)
 38. Collard KJ: **Iron homeostasis in the neonate**. *Pediatrics*. 2009; **123**(4): 1208–16.
[PubMed Abstract](#) | [Publisher Full Text](#)
 39. Dominguez-Bello MG, Costello EK, Contreras M, *et al.*: **Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns**. *Proc Natl Acad Sci U S A*. 2010; **107**(26): 11971–11975.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 40. Houghteling PD, Walker WA: **Why is initial bacterial colonization of the intestine important to infants' and children's health?** *J Pediatr Gastroenterol Nutr*. 2015; **60**(3): 294–307.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 41. Basha S, Surendran N, Pichichero M: **Immune responses in neonates**. *Expert Rev Clin Immunol*. 2014; **10**(9): 1171–84.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 42. Lipiński P, Styś A, Starzyński RR: **Molecular insights into the regulation of iron metabolism during the prenatal and early postnatal periods**. *Cell Mol Life Sci*. 2013; **70**(1): 23–38.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 43. Lorenz L, Peter A, Poets CF, *et al.*: **A review of cord blood concentrations of iron status parameters to define reference ranges for preterm infants**. *Neonatology*. 2013; **104**(3): 194–202.
[PubMed Abstract](#) | [Publisher Full Text](#)
 44. Lorenz L, Herbst J, Engel C, *et al.*: **Gestational age-specific reference ranges of hepcidin in cord blood**. *Neonatology*. 2014; **106**(2): 133–139.
[PubMed Abstract](#) | [Publisher Full Text](#)
 45. Ru Y, Pressman EK, Guillet R, *et al.*: **Umbilical Cord Hepcidin Concentrations Are Positively Associated with the Variance in Iron Status among Multiple Birth Neonates**. *J Nutr*. 2018; **148**(11): 1716–1722.
[PubMed Abstract](#) | [Publisher Full Text](#)
 46. Szabó M, Vársárhelyi B, Balla G, *et al.*: **Acute postnatal increase of extracellular antioxidant defence of neonates: the role of iron metabolism**. *Acta Paediatr*. 2001; **90**(10): 1167–1170.
[PubMed Abstract](#) | [Publisher Full Text](#)
 47. Sturgeon P: **Studies of iron requirements in infant and children. I. Normal values for serum iron, copper and free erythrocyte protoporphyrin**. *Pediatrics*. 1954; **13**(2): 107–25.
[PubMed Abstract](#)
 48. Ballard JL, Khoury JC, Wedig K, *et al.*: **New Ballard Score, expanded to include extremely premature infants**. *J Pediatr*. 1991; **119**(3): 417–23.
[PubMed Abstract](#) | [Publisher Full Text](#)
 49. Cross J, Jarjou O, Mohammed NI: **Cross *et al.* GatesOpen Research SCC1525v2__Neolnnate_Participant Info&Consent form Route 1. figshare**. Figure. 2019.
<http://www.doi.org/10.6084/m9.figshare.8069195.v4>
 50. Cross J, Jarjou O, Mohammed NI, *et al.*: **Cross *et al.* GatesOpenResearch SCC1525v2__Neolnnate__Consent form Route 2_Part 1_(Umbilical Cord Blood Collection) - Labour Ward_v1.1-Approved 8Nov17. figshare**. Figure. 2019.
<http://www.doi.org/10.6084/m9.figshare.8069246.v1>
 51. Cerami C, Cross J, Jarjou O, *et al.*: **Cross *et al.* Gates Open Research SCC1525v2__Neolnnate__Consent form Route 2_Part 2_(Post-Delivery) - ANC Outside SGH v1-Approved 8Nov17. figshare**. Figure. 2019.
<http://www.doi.org/10.6084/m9.figshare.8069243.v1>
 52. **WHO | Delayed umbilical cord clamping for improved maternal and infant health and nutrition outcomes**. WHO, 2018.
[Reference Source](#)
 53. Cross JH, Bradbury RS, Fulford AJ, *et al.*: **Oral iron acutely elevates bacterial growth in human serum**. *Sci Rep*. 2015; **5**: 16670.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 54. Moore SE, Fulford AJ, Streatfield PK, *et al.*: **Comparative analysis of patterns of survival by season of birth in rural Bangladeshi and Gambian populations**. *Int J Epidemiol*. 2004; **33**(1): 137–143.
[PubMed Abstract](#) | [Publisher Full Text](#)
 55. Skaar EP: **The battle for iron between bacterial pathogens and their vertebrate hosts**. *PLoS Pathog*. 2010; **6**(8): e1000949.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 56. Lee AC, Panchal P, Folger L, *et al.*: **Diagnostic Accuracy of Neonatal Assessment for Gestational Age Determination: A Systematic Review**. *Pediatrics*. 2017; **140**(6): pii: e20171423.
[PubMed Abstract](#) | [Publisher Full Text](#)
 57. Benson CB, Doubilet PM: **Sonographic prediction of gestational age: accuracy of second- and third-trimester fetal measurements**. *AJR Am J Roentgenol*. 1991; **157**(6): 1275–1277.
[PubMed Abstract](#) | [Publisher Full Text](#)
 58. Sebastiani G, Wilkinson N, Pantopoulos K: **Pharmacological Targeting of the Hepcidin/Ferroportin Axis**. *Front Pharmacol*. 2016; **7**: 160.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Open Peer Review

Current Peer Review Status:  

Version 1

Reviewer Report 19 September 2019

<https://doi.org/10.21956/gatesopenres.14069.r27774>

© 2019 Sangkhae V. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



Veena Sangkhae 

Center for Iron Disorders, David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA, USA

The observational study proposed by Cross *et al* aims to study the role of neonatal iron metabolism on the susceptibility of neonates to infection. Subjects will be recruited in Serrekunda and deliver at Kanifing General Hospital in The Gambia, West Africa. The study will include 4 groups: 1) full-term normal birthweight, 2) full-term low birthweight, 3) preterm normal birthweight and 4) preterm low birthweight neonates. At delivery, blood will be collected from the umbilical arteries and vein. In addition, neonatal venous blood will be collected between 6 and 24hrs following delivery. A full hematology panel will be performed on whole blood and various inflammatory markers and iron status indicators will be measured in serum. The primary objective of the study is to determine how full term, preterm and low birthweight neonates regulate their serum iron in the 24 hours after birth. Cross *et al* hypothesize that preterm and/or low birthweight neonates will be unable to sufficiently regulate serum iron levels and transferrin saturation, thus making them more susceptible to infection.

The rationale for, and objectives of the study are clearly described. Neonatal infection remains a major global health concern and gaining a detailed understanding of iron metabolism in neonates and their susceptibility to infection may facilitate better monitoring practices, development of improved diagnostics and novel therapies.

The study design is appropriate for the research question. Measurement of neonatal serum iron concentration and transferrin saturation will provide information on the bioavailability of iron at baseline for microorganisms. Determining *ex vivo* growth of microorganisms in sera from term and preterm neonates will provide additional information on the susceptibility of neonates to infection. However, inclusion of neonates that have received immunizations prior to the 1st venous blood draw at 6-24 post-delivery may introduce a confounding factor. In adults, 24hrs following immunization, both IL-6 and hepcidin are significantly increased (Stoffel *et al.* 2019¹). Thus, for the 2nd venous blood draw of the full-term normal birthweight group, it may be useful to delay the blood draw if a neonate has received an immunization within the previous 24hrs. An additional

point that needs some clarification is exclusion criteria delta which lists cord blood processed >3hrs. However, for route 2 enrollment, cord blood will be collected and stored until consent is obtained which is listed at 2-6hrs following delivery, which could mean a large number of route 2 enrollment samples are excluded, could you please provide clarification.

The methods provided for the most part allow for replication by others but some of the details are not included. The manner of blood collection (whole blood in EDTA, serum), time ranges and storage conditions are listed; however, details regarding processing and storage are missing. Will all samples be processed for all of the parameters immediately after collection or will parameters in whole blood processed immediately but serum collected and stored at -20C and processed together following collection of all samples? The panel of cytokines and iron status indicators to be measured are listed; however, for samples analyzed by ELISA, it would be informative to list the specifics of each ELISA (i.e. manufacturer).

Authors sufficiently indicate the limitations of the study. However, despite these limits, the data gathered will provide valuable insight into iron regulation during this period of human development. This study is of great interest as neonates are at greater risk of infection due to their underdeveloped immune systems, yet nutritional immunity including neonatal iron regulation and distribution is not well characterized. Although the iron-infection axis has been extensively studied in the adult population, it is understudied in neonates. This is specifically of interest in regions where neonatal infections are common. Vaginal birth, a requirement in this study, is associated with increased inflammation, which induces hepcidin in the mother and has been postulated to increase hepcidin in the fetus. This is a confounding factor in some studies as conclusions regarding hepcidin and iron regulation at delivery are made using cord blood which likely has elevated hepcidin due to inflammation associated with delivery. It is unique and important that this study will provide information from neonatal blood at >24 to <80h; >80h to <136; and >136h to <192h after delivery. The proposal to measure both cord blood in addition to neonatal blood will inform on whether cord blood is an accurate indicator of neonatal iron status. Not only will this study provide an increased understanding of nutritional immunity in neonates, it will also provide much needed information on iron homeostasis during the neonatal period.

References

1. Stoffel NU, Lazrak M, Bellitir S, Mir NE, et al.: The opposing effects of acute inflammation and iron deficiency anemia on serum hepcidin and iron absorption in young women. *Haematologica*. 2019; **104** (6): 1143-1149 [PubMed Abstract](#) | [Publisher Full Text](#)

Is the rationale for, and objectives of, the study clearly described?

Yes

Is the study design appropriate for the research question?

Yes

Are sufficient details of the methods provided to allow replication by others?

Partly

Are the datasets clearly presented in a useable and accessible format?

Not applicable

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Iron homeostasis, pregnancy, placental iron transport, cytokine biology, cell signaling

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Author Response 02 Oct 2019

Carla Cerami, MRC Unit The Gambia at the London School of Hygiene & Tropical Medicine, Fajara, The Gambia

Query: The study design is appropriate for the research question. Measurement of neonatal serum iron concentration and transferrin saturation will provide information on the bioavailability of iron at baseline for microorganisms. Determining *ex vivo* growth of microorganisms in sera from term and preterm neonates will provide additional information on the susceptibility of neonates to infection.

However, inclusion of neonates that have received immunizations prior to the 1st venous blood draw at 6-24 post-delivery may introduce a confounding factor. In adults, 24hrs following immunization, both IL-6 and hepcidin are significantly increased (Stoffel *et al.* 2019¹). Thus, for the 2nd venous blood draw of the full-term normal birthweight group, it may be useful to delay the blood draw if a neonate has received an immunization within the previous 24hrs.

Response:

Please note that this same question has also been raised by Dr Stefanova.

According to current practice, the vaccination of neonates at Kanifing General Hospital (The Gambia), occurs at a later time point due to social and logistical reasons. However, the mothers will be asked whether the neonate has been vaccinated at the health check before the 1st venous bleed takes place. The answers will be recorded and this data will be included in the final report.

The embedded observational study (which includes only full-term babies) includes a home visit up to seven days after birth for a health check and collection of a 2nd venous blood sample. At this visit data will also be collected on the type, time and date of vaccination. The effect of vaccination on iron and inflammatory parameters in the first week of life will be analysed as part of the formal data analysis plan.

Query:

An additional point that needs some clarification is exclusion criteria delta which lists cord blood processed >3hrs. However, for route 2 enrolment, cord blood will be collected and stored until consent is obtained which is listed at 2-6hrs following delivery, which could mean a large number of route 2 enrolment samples are excluded, could you please provide clarification.

Response:

To clarify, mothers will be approached 2-6 hours following delivery. Samples will still be processed up until 6 hours post-collection. This information will be recorded and assessed as part of the formal data analysis plan. Any values that are greater or lesser than 5 standard deviations of the mean will be regarded as outliers and removed.

Query:

The methods provided for the most part allow for replication by others but some of the details are not included. The manner of blood collection (whole blood in EDTA, serum), time ranges and storage conditions are listed; however, details regarding processing and storage are missing. Will all samples be processed for all of the parameters immediately after collection or will parameters in whole blood processed immediately but serum collected and stored at -20C and processed together following collection of all samples?

Response:

The processing of samples will be conducted 1-3 hours after collection to allow serum samples to coagulate and to allow mothers admitted via route 2 to give written consent. Whole blood in EDTA will be run using the Medonic M20M GP (Boule Diagnostics, Spanga, Sweden) after inversion of the blood collection tube 5 times. Remaining whole blood samples will be aliquoted into 2ml Sarstedt micro tubes (SARSTEDT AG & Co. KG, Germany) and frozen at -20°C. G6PD deficiency testing (R&D Diagnostics Limited, Papagos, Greece) will be conducted at the end of the recruitment period in the study.

The Serum-Gel blood collection tube (SARSTEDT AG & Co. KG, Germany) will be centrifuged at 3500rpm for 10 mins using an Eppendorf Centrifuge 5702 (Eppendorf, Germany). Serum will be aliquoted into 2ml Sarstedt micro tubes (SARSTEDT AG & Co. KG, Germany), boxed and labelled before being stored at -20°C until after the recruitment period. All laboratory analysis of iron and inflammatory parameters will be conducted as one batch.

The panel of cytokines and iron status indicators to be measured are listed; however, for samples analyzed by ELISA, it would be informative to list the specifics of each ELISA (i.e. manufacturer).

Response:

DRG Hepcidin 25 (bioactive) HS ELISA (EIA-5782) (dynamic range: 0.135 - 81 ng/mL), made by DRG Instruments GmbH, Germany, will be used to measure serum hepcidin. The results of the DRG ELISA (ng/nl hepcidin) will be presented along with the standardised hepcidin results as described in Van der Vorm et al¹.

1. van der Vorm, L. N. *et al.* Toward Worldwide Hepcidin Assay Harmonization: Identification of a Commutable Secondary Reference Material. *Clin. Chem.* **62**, 993–1001 (2016).

Competing Interests: None.

Reviewer Report 03 September 2019

<https://doi.org/10.21956/gatesopenres.14069.r27647>

© 2019 Stefanova D. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



Deborah Stefanova

Institute for Molecular Health Sciences, ETH Zurich, Zurich, Switzerland

The study by Cross *et al.* proposes to investigate whether regulation of iron metabolism during the first 24h of life differs between full-term normal birth weight newborns and newborns that are either low birth weight, pre-term or both. For this purpose, blood will be collected for analysis from the umbilical cord and compared to venous blood collected from the newborns at 6 to 24h post-delivery. In addition, an observational study to gain insight into neonatal iron metabolism during the first 8 days of life will be conducted within the full-term normal birth weight newborns group. The obtained blood will be analyzed for various iron parameters, cytokines, full haematology count etc. The authors hypothesize that newborns that are either low birth weight, pre-term or both will be unable to efficiently decrease transferrin saturation (TSAT) and serum iron and as a result they will become more susceptible to infections. In order to partially address this hypothesis, different bacteria that commonly infect newborns in the region where the study is conducted, will be cultured in plasma obtained from each group of newborns and bacterial growth will be compared.

The rationale and the objectives of the study are clearly defined. The study design appropriately addresses the research question and offers one of the first studies where blood from newborns will be analyzed at 6h to 192h post-delivery. Many studies so far have focused predominantly on umbilical cord blood, which while informative, can also be quite misleading since the stress of birth has significant effect on hepcidin production and thus on iron parameters. The methods are described clearly and in detail.

It would be good if at Route 2 of study enrolment, where the mothers will be invited to provide written consent at 2-6h post-delivery, a brief assessment of the psychological state of the mother is done beforehand since 2-6h is still quite early after giving birth. In addition, immunizations are not an exclusion criteria for newborn blood collection in this study, which makes sense since most newborns receive immunizations within the first 24h of their life. However, activating the immune response has an effect of hepcidin production so a note should be taken on whether or not a newborn has been immunized before blood collection for future reference. Lastly, the cited method for growing bacteria in human plasma uses 50% human plasma but it is not clear what composes the other 50% of the culture medium (whether it is regular commercial growth medium such as Luria-Bertani or some kind of buffer). It is important to define that, since commercial growth medium contains small but sufficient amount of free iron, which is readily available for bacterial acquisition and could affect bacterial growth. If possible, the bacteria could be cultured in 90-100% human plasma to avoid such confounding factors.

The study by Cross *et al.* addresses a very interesting and important biological question regarding

the regulation of iron metabolism in neonates and its relevance for susceptibility to infection. I expect that the information gathered through this study will contribute significantly to the knowledge in the community.

Is the rationale for, and objectives of, the study clearly described?

Yes

Is the study design appropriate for the research question?

Yes

Are sufficient details of the methods provided to allow replication by others?

Yes

Are the datasets clearly presented in a useable and accessible format?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Iron metabolism, infections, signaling, growth factors biology.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Author Response 02 Oct 2019

Carla Cerami, MRC Unit The Gambia at the London School of Hygiene & Tropical Medicine, Fajara, The Gambia

Query:

It would be good if at Route 2 of study enrolment, where the mothers will be invited to provide written consent at 2-6h post-delivery, a brief assessment of the psychological state of the mother is done beforehand since 2-6h is still quite early after giving birth.

Response:

Mothers will be approached 2-6 hours post-delivery on a one-to-one basis by our research clinician. The research clinician will independently verify if the mother displays normal psychological function and is not under distress before the consenting process begins. Good clinical practise will be followed at all times.

Query:

In addition, immunizations are not an exclusion criteria for newborn blood collection in this study, which makes sense since most newborns receive immunizations within the first 24h of their life. However, activating the immune response has an effect of hepcidin production so a note should be taken on whether or not a newborn has been immunized before blood collection for future reference.

Response:

According to current practice, the vaccination of neonates at Kanifing General Hospital (The Gambia), occurs at a later time point due to social and logistical reasons. However, the mothers will be asked whether the neonate has been vaccinated at the health check before the 1st venous bleed takes place. The answers will be recorded and this data will be included in the final report.

The embedded observational study (which includes only full-term babies) includes a home visit up to seven days after birth for a health check and collection of a 2nd venous blood sample. At this visit data will also be collected on the type, time and date of vaccination. The effect of vaccination on iron and inflammatory parameters in the first week of life will be analysed as part of the formal data analysis plan.

Query:

Lastly, the cited method for growing bacteria in human plasma uses 50% human plasma but it is not clear what composes the other 50% of the culture medium (whether it is regular commercial growth medium such as Luria-Bertani or some kind of buffer). It is important to define that, since commercial growth medium contains small but sufficient amount of free iron, which is readily available for bacterial acquisition and could affect bacterial growth. If possible, the bacteria could be cultured in 90-100% human plasma to avoid such confounding factors.

Response:

The culture medium used will be iron free minimal growth media, Iscove's Modified Dulbecco's Medium (IMDM, Invitrogen). The *ex vivo* bacterial growth assay has been previously conducted in pilot experiments, using 90-100% human serum, however, growth rates diminished to a level that was difficult to detect.

Competing Interests: None.